Sanofi | SNY - Cash And Equivalent




Sanofi reported 6.8B in Cash and Equivalent for its fiscal quarter ending in June of 2024.

Cash And Equivalent Change Date
AbbVie USD 7.26B 5.87B Sep/2024
Amgen USD 11.97B 2.96B Dec/2024
AstraZeneca USD 5.49B 691M Dec/2024
Bristol-Myers Squibb USD 10.35B 2.46B Dec/2024
Canopy Growth CAD 86.12M 106.04M Sep/2024
Corcept Therapeutics USD 137.29M 8.7M Sep/2024
Drreddys Laboratories INR 353M 263M Sep/2024
Eli Lilly USD 3.37B 145.4M Sep/2024
Galapagos EUR 64.24M 8.72M Dec/2024
Genmab DKK 9.86B 3.52B Dec/2024
GlaxoSmithKline GBP 3.87B 678M Dec/2024
Glaxosmithkline GBP 3.19B 230M Sep/2024
Indivior 288M 14M Sep/2024
J&J USD 4.85B 20.03B Sep/2024
Merck USD 14.59B 3.29B Sep/2024
Novartis USD 8.87B 4.74B Dec/2024
Novartis USD 13.61B 5.71B Sep/2024
Pacira USD 245.96M 1.08M Sep/2024
Perrigo USD 1.46B 920.7M Sep/2024
Pfizer USD 1.09B 40M Sep/2024
Prestige Brands USD 50.87M 666K Dec/2024
Roche Holding CHF 6.98B 2.15B Dec/2024
Sanofi 6.8B 1.92B Jun/2024
Sanofi 6.8B 1.92B Jun/2024
Supernus Pharmaceuticals USD 31.67M 20.42M Sep/2024
UCB EUR 428M 433M Jun/2024
Zoetis USD 1.99B 273M Dec/2024